Join our Clinical Trial

We are committed to disrupting cancer’s energy through misetionamide, our therapeutic, which brings about cancer cell death through a combination of metabolic and oxidative stress as well as impacting the cancer cell’s ability to survive and proliferate. Beginning with our clinical trials in pancreatic cancer, we are focused on addressing cancer types that are difficult to treat and have a clear unmet need. Through our continued research and clinical trials, we aim to reach patients around the world who are experiencing advanced or aggressive cancers.

For Clinicians

Switch

For Patients

Why Participate

What You Should Know

Misetionamide has demonstrated an excellent safety profile in preclinical studies and continues to show very good tolerability in the ongoing Phase 1 clinical trial.
Our research has demonstrated that misetionamide has powerful synergies with existing oncology therapies.
A currently enrolling clinical trial is focused on pancreatic cancer.
Panavance’s research and clinical development is done in collaboration with renowned clinical experts, scientists, industry professionals, and organizations.
Our clinician participants are key to advancing our scientific and medical knowledge during our path to market.

How to Learn More

If you are a clinician who is interested in learning more about our existing clinical trials, please fill out the form below.

Why Participate

What You Should Know

Our participating patients gain the opportunity to access an experimental oncology treatment that is based on truly novel science while advancing science and medical care.
A currently enrolling clinical study is focused on pancreatic cancer.
Panavance’s research and clinical development is done in collaboration with reknowned clinical experts, scientists, industry professionals, and organizations.
Our patient participants play an essential role in advancing our knowledge of therapeutic interventions, which ultimately benefits patients everywhere.
Patients may benefit from clinical trial participation if a drug demonstrates efficacy, but there is no guarantee that participants will benefit. Research studies may benefit future patients with the same cancer or with a different type of cancer.

NOTE: Misetionamide is still under clinical development and has not been approved by the FDA or any other regulatory agency for the treatment of any tumor type.

How to Learn More

If you are a patient who is interested in learning more about our existing clinical trials, please fill out the form below.

Leadership

Meet the Panavance Leadership Team.

We are led by a highly capable and passionate team that shares wholeheartedly in our mission.

Science

Discover our novel mechanism of action.

Our mechanism of action that suppresses cancers by disrupting their energy metabolism, bringing about cancer cell death.